Corticosteroid suppression of lipoxin A₄ and leukotriene B₄ from alveolar macrophages in severe asthma

Pankaj K Bhavsar¹, Bruce D Levy², Mark J Hew¹, Michael A Pfeffer², Shamsah Kazani², Elliot Israel² and Kian Fan Chung*¹

Abstract

Background: An imbalance in the generation of pro-inflammatory leukotrienes, and counter-regulatory lipoxins is present in severe asthma. We measured leukotriene B₄ (LTB₄) and lipoxin A₄ (LXA₄) production by alveolar macrophages (AMs) and studied the impact of corticosteroids.

Methods: AMs obtained by fiberoptic bronchoscopy from 14 non-asthmatics, 12 non-severe and 11 severe asthmatics were stimulated with lipopolysaccharide (LPS, 10 μg/ml) with or without dexamethasone (10⁻⁶ M). LTB₄ and LXA₄ were measured by enzyme immunoassay.

Results: LXA₄ biosynthesis was decreased from severe asthma AMs compared to non-severe (p < 0.05) and normal subjects (p < 0.001). LXA₄ induced by LPS was highest in normal subjects and lowest in severe asthmatics (p < 0.01). Basal levels of LTB₄ were decreased in severe asthmatics compared to normal subjects (p < 0.05), but not to non-severe asthma. LPS-induced LTB₄ was increased in severe asthma compared to non-severe asthma (p < 0.05). Dexamethasone inhibited LPS-induced LTB₄ and LXA₄, with lesser suppression of LTB₄ in severe asthma patients (p < 0.05). There was a significant correlation between LPS-induced LXA₄ and FEV₁ (% predicted) (rs = 0.60; p < 0.01).

Conclusions: Decreased LXA₄ and increased LTB₄ generation plus impaired corticosteroid sensitivity of LPS-induced LTB₄ but not of LXA₄ support a role for AMs in establishing a pro-inflammatory balance in severe asthma.

Introduction

Patients with asthma are usually well-controlled with inhaled corticosteroids (CS) and long-acting β₂-agonists, but a minority of patients described as severe asthma continues to experience uncontrolled asthma in spite of these treatments. Patients with severe asthma suffer greater morbidity, face a higher risk of asthma death, and consume a greater proportion of health resources than other non-severe asthma patients [1,2]. One feature of severe asthma is the presence of airway inflammation despite corticosteroid therapy, often characterised by the persistence of eosinophilic inflammation and the presence of neutrophils [3,4]. Persistent symptoms with frequent exacerbations of asthma despite corticosteroid therapy also indicate the possibility that CS may not be as effective in patients with severe asthma. The presence of reduced CS sensitivity in severe asthma is supported by the finding that release of cytokines from peripheral blood mononuclear cells and alveolar macrophages is less suppressible by dexamethasone than those from non-severe asthma patients [5,6].

Lipid mediators of the 5-lipoxygenase pathway such as cysteinyl-leukotrienes are implicated as mediators of airway bronchoconstriction and eosinophilic inflammation in asthma; another product, leukotriene B₄ (LTB₄), has also been implicated, particularly in view of its chemoattractant and activating properties for neutrophils [7]. Similar to LTs, lipoxins (LXs) are products of arachidonic
acid metabolism, yet LXs are generated via interactions between 5- and 15-lipoxygenases or 5- and 12-lipoxygenases to form structurally distinct compounds that promote the resolution of inflammation. Thus, LXs are counter-regulatory to the cysteinyll-leukotrienes and LTB₄ [8]. The possibility that dysregulation of the balance among these arachidonic acid products might contribute to the persistent inflammation in severe asthma has been supported by the demonstration of an increased generation of cysteinyll-leukotrienes with impaired biosynthesis of lipoxin A₄ (LXA₄) from whole blood of patients with severe asthma compared to non-severe asthma patients [9]. In addition, LXA₄ levels in bronchoalveolar lavage fluid of patients with severe asthma from the NHLBI Severe Asthma Research Program were decreased when compared to non-severe asthma patients [10].

We determined whether an imbalance in pro-inflammatory LTB₄ and anti-inflammatory LXA₄ in the lungs of patients with severe asthma could be reflected in the formation of these products from alveolar macrophages (AMs). We also determined whether there would also be a differential suppressibility of these mediators that reflect different effects in asthma.

**Methods**

**Patients**

Patients with asthma were recruited from the Asthma Clinic of the Royal Brompton Hospital, London. Severe asthma patients underwent the Royal Brompton severe asthma protocol, in order to confirm the diagnosis and to maximise treatments [11]. All patients showed either an improvement in baseline FEV₁ of ≥12% over baseline values after inhalation of 400 µg of salbutamol aerosol, or the presence of bronchial hyperresponsiveness defined by methacholine PC₂₀ of < 4 mg/ml. Current and ex-smokers of ≥5 pack-years were excluded. Severe asthmatics were defined according to the American Thoracic Society major criteria of needing either continuous or near-continuous oral corticosteroids or high dose inhaled corticosteroids (2,000 µg beclomethasone-equivalent per day or more) or both in order to achieve a level of mild-moderate persistent asthma, and by 2 or more minor criteria of asthma control [12]. Patients who had well-controlled asthma defined by the lack of day-time or nocturnal symptoms and no need for reliever medications while using ≤ 800 µg of inhaled beclomethasone-equivalent per day were enrolled into the non-severe asthma group. Healthy volunteers with no diagnosis of asthma and with a negative PC₂₀ (>16 mg/ml), using no medications and never-smokers, were also recruited. All participants gave informed consent to a protocol approved by the Ethics Committee of Royal Brompton & Harefield NHS Trust/ National Heart & Lung Institute.

**Fiberoptic bronchoscopy**

All asthmatic subjects received 5 mg of nebulised salbutamol before the procedure. Fiberoptic bronchoscopy was performed using topical anesthesia with lignocaine and intravenous sedation with midazolam. Warmed 0.9% NaCl solution (50 ml × 4) was instilled into the right middle lobe and recovery of broncho-alveolar lavage (BAL) fluid was carried out by gentle hand suction.

**Alveolar macrophage isolation**

BAL cells were centrifuged (500 × g for 10 minutes) and washed with Hanks’ balanced salt solution (HBSS). They were resuspended in culture media (RPMI with 0.5% fetal calf serum, antibiotics and L-glutamine) and counted using Kimura dye. Cytospins were prepared and stained with Diff Quick (Harleco, Gibbstown, NJ) stain for differential cell count. 5×10⁵ macrophages were isolated by stimulatory LXA₄ levels in both neat and spiked samples. Addition of authentic LXA₄ increased the total amount of LXA₄ (endogenous plus exogenous) above the lower limits of detection for the ELISA. Neat and spiked samples displayed only minor variance in the amount of endogenous LXA₄.

**Data analysis**

Results are expressed as means ± SEM. The differences in LTB₄ and LXA₄ generated at baseline were compared using one-way analysis of variance with Dunn’s multiple comparison test. Differences between LPS and LPS plus dexamethasone treatment were analysed using Wilcoxon paired t-tests and in this case differences between groups were compared using Mann-Whitney t-test. Correlations
were performed using Spearman’s rank tests. p < 0.05 was taken as significant.

**Results**
Severe asthmatics had more severe airflow obstruction (p < 0.05) and bronchial hyperresponsiveness (p < 0.05) compared to non-severe asthmatics (Table 1). They were also on higher doses of inhaled corticosteroids (p < 0.05). BAL yielded fewer cells from severe asthmatics compared to non-severe asthmatics (p = 0.06), but there were proportionately more eosinophils (p < 0.05) and neutrophils (p < 0.05) with fewer macrophages (p < 0.01) in severe asthma compared to non-severe asthma.

**Baseline and LPS-stimulated generation of LXA₄**
Low levels of LXA₄ were generated by AMs in culture. The baseline LXA₄ from AMs obtained from normal subjects was higher than that from both non-severe (p < 0.05) and severe asthmatics (p < 0.01; Figure 1A). There was a significant difference between non-severe and severe asthmatics (p < 0.05) with a three-fold higher baseline level in non-severe asthmatics. The LXA₄ production induced by LPS is shown as the increment in LXA₄ above baseline (Figure 1B). There was a small but significant increase in LPS-induced LXA₄ levels in all three groups (Figure 1B), with the lowest amounts in severe compared to non-severe asthma (p < 0.01) and to normal subjects (p < 0.001).

There was a negative correlation between baseline LXA₄ levels in asthmatic patients and the percentage of neutrophils in the BAL (rₛ = -0.42, p < 0.05), and a positive correlation between LPS-induced LXA₄ levels from asthmatic patients and FEV₁ (% predicted; r = 0.60, p < 0.01). In addition, there was a negative correlation between percentage neutrophils in the BAL and FEV₁ (rₛ = -0.65, p < 0.001).

**Basal and LPS-stimulated generation of LTB₄**
The basal level of LTB₄ from AMs obtained from normal subjects was higher than that from both non-severe (p < 0.05) and severe asthmatics (p < 0.05; Figure 2A), with no significant differences between non-severe and severe asthmatics. The LTB₄ production induced by LPS is shown as increments in LTB₄ above baseline (Figure 2B). LPS induced LTB₄ generation in all three groups (p < 0.05), but the increase in LTB₄ in severe asthma patients was 5-fold greater than in non-severe asthmatics (p < 0.05; Figure 2B).

**Table 1: Characteristics of subjects**

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Non-Severe asthma</th>
<th>Severe asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>14</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td><strong>Age (yr)</strong></td>
<td>21 ± 0.4</td>
<td>43 ± 3</td>
<td>47 ± 3</td>
</tr>
<tr>
<td><strong>Atopy</strong></td>
<td>0/14</td>
<td>11/12</td>
<td>9/11</td>
</tr>
<tr>
<td><strong>M/F</strong></td>
<td>12/2</td>
<td>7/5</td>
<td>4/7</td>
</tr>
<tr>
<td><strong>FEV¹ (% Predicted)</strong></td>
<td>98 ± 3</td>
<td>85 ± 3</td>
<td>58 ± 6*</td>
</tr>
<tr>
<td><strong>PC20 (mg/ml)</strong></td>
<td>&gt;16</td>
<td>5.73 ± 2.7</td>
<td>0.64 ± 0.14*</td>
</tr>
<tr>
<td><strong>Inhaled corticosteroid</strong></td>
<td>0</td>
<td>527 ± 239 (n = 6)</td>
<td>2400 ± 414* (n = 11)</td>
</tr>
<tr>
<td><strong>Oral prednisolone (mg/day)</strong></td>
<td>0</td>
<td>0</td>
<td>19.1 ± 3.2 (n = 6)</td>
</tr>
<tr>
<td><strong>Total BAL Cells (x 10⁶)</strong></td>
<td>9.19 ± 1.4</td>
<td>8.36 ± 0.8</td>
<td>6.1 ± 0.99</td>
</tr>
<tr>
<td><strong>BAL-Macs (x 10⁶)</strong></td>
<td>9.02 ± 1.32</td>
<td>8.17 ± 0.76</td>
<td>5.81 ± 1.00</td>
</tr>
<tr>
<td><strong>BAL-Neu (x 10⁶)</strong></td>
<td>0.1 ± 0.03</td>
<td>0.063 ± 0.016</td>
<td>0.15 ± 0.03</td>
</tr>
<tr>
<td><strong>BAL-Eos (x 10⁶)</strong></td>
<td>0.018 ± 0.012</td>
<td>0.026 ± 0.012</td>
<td>0.07 ± 0.03</td>
</tr>
<tr>
<td><strong>BAL-Mac (%)</strong></td>
<td>97.9 ± 0.5</td>
<td>97.8 ± 0.4</td>
<td>92.9 ± 1.5**</td>
</tr>
<tr>
<td><strong>BAL-Neu (%)</strong></td>
<td>1.03 ± 0.3</td>
<td>0.8 ± 0.2</td>
<td>3 ± 0.7*</td>
</tr>
<tr>
<td><strong>BAL-Eos (%)</strong></td>
<td>0.21 ± 0.09</td>
<td>0.29 ± 0.14</td>
<td>1.4 ± 0.55*</td>
</tr>
</tbody>
</table>

Abbreviations: M = Male; F = Female; BAL = Bronchoalveolar lavage; BDP = Beclomethasone dipropionate; Neu = neutrophils; Eos = eosinophils; Mac = macrophage. Data shown as mean ± SEM. *p < 0.05; **p < 0.01 compared to non-severe asthma.
Dexamethasone suppression of LXA₄ and LTB₄

Dexamethasone suppression of LPS-initiated LXA₄ was significant in all three groups (p < 0.05), with no significant differences between the groups (Figure 3). Dexamethasone suppression of LTB₄ was observed in all three groups: normal subjects (LPS: 102 ± 23 versus LPS and dexamethasone: 11.6 ± 7.7 pg/ml, p < 0.05); non-severe asthmatics (183 ± 122 versus 21.4 ± 22 pg/ml, p < 0.05) and severe asthmatics (230 ± 102 versus 60 ± 32 pg/ml, p < 0.01). When the suppression was expressed as a percentage of LPS-induced eicosanoid production, there was no significant differences observed between normal and non-severe asthmatics with ~90% suppression. However, there was a lesser degree of suppression in severe asthmatics (Figure 4).

In macrophages from normal subjects, the ratio of LTB₄ to LXA₄ (using pg/ml) was unchanged after exposure to LPS or to LPS plus dexamethasone. In non-severe asthmatics, both LPS and LPS plus dexamethasone gave an increased LTB₄/LXA₄ ratio, but only in severe asthmatics was the increase induced by LPS and dexamethasone significantly greater than that induced by LPS alone (p < 0.05) (Figure 5). In addition, LTB₄/LXA₄ ratios after LPS and dexamethasone were significantly greater in severe asthmatics compared to non-severe asthmatics (p < 0.05).
as a result of both an increase in LTB₄ and a decrease in LXA₄ compared to normal subjects.

**Discussion**

We have shown that the basal generation of the pro-inflammatory LTB₄ and the anti-inflammatory LXA₄ were both lower in cultured AMs from severe asthmatics compared to those from non-asthmatics, while only LXA₄ was lower in severe asthmatics compared to non-severe asthmatics. The LPS induced formation of LTB₄ was higher in severe asthma compared to non-severe asthma and normal subjects, while the LPS induced production of LXA₄ was significantly impaired in severe asthmatics compared to normal subjects, but to a similar extent as in non-

severe asthma patients. The overall effect of LPS stimulation was a net pro-inflammatory balance in terms of enhanced generation of LTB₄, and a decrease in LXA₄ compared to AMs from normal subjects. In addition, while the LPS-induced LTB₄ was largely suppressed by dexamethasone, it was only partly suppressed in AMs from severe asthma patients; by contrast, induced generation of LXA₄ was suppressed in all three groups. Therefore, the overall balance of these 2 lipid mediators in severe asthma was in favour of an overall pro-inflammatory response through both increased production and relative corticosteroid insensitivity of LTB₄ and decreased levels of LXA₄ in severe asthmatics, as illustrated by the LTB₄ to LXA₄ ratios.

Human AMs can generate both 5-lipoxygenase and 15-lipoxygenase derived eicosanoids, including LTB₄ and
LXA₄ from endogenous sources of arachidonic acid[13]. LXA₄ generation from endogenous stores is low, but LX biosynthesis can be amplified by select TH2 cytokines, namely interleukin-4 and interleukin-13 [14,15]. In addition, exogenous LTA₄ can be converted by AMs to more substantial amounts of LXs [16], as would occur during transcellular biosynthesis with LTA₄ donation from one cell to a second cell for enzymatic conversion by either 12- or 15-lipoxygenase to LXs. Our studies are the first to document both LTB₄ and LXA₄ generation from human AMs from asthmatic subjects. Although the levels of LXA₄ are low, they were detected reproducibly, validated with authentic material and picogram quantities of LXs are biologically active in resolving inflammation (reviewed in reference [17]). Interestingly, when the data was expressed as a ratio of pro-inflammatory LTB₄ to anti-inflammatory LXA₄, there was an increased pro-inflammatory imbalance when the macrophages from both asthmatic groups were exposed to LPS, and this was not reversed by corticosteroids. Indeed, in macrophages from severe asthma, this pro-inflammatory ratio favouring LTB₄ over LXA₄ was further unbalanced by dexamethasone.

Our results indicate that the pulmonary macrophage can be an important source of lipid mediators, and that differences in LTB₄ and LXA₄ between the asthmatic groups are in general agreement with recent studies that have examined levels in whole blood[9,18] and BAL fluids [10]. In the study of Wenzel et al, levels of LTB₄ in BAL fluid from severe asthma were the highest compared to levels from moderate symptomatic asthma patients and normals [19]. This indicates that the baseline contribution of LTB₄ from macrophages is unlikely to explain this increased levels found in BAL of severe asthma patients; however, following ex vivo stimulation of macrophages from severe asthma patients, greater levels of LTB₄ were released compared to non-severe asthma patients. Using a similar method as our study to distinguish severe from non-severe asthma, a deficiency in both baseline and divergent cation ionophore-stimulated production of LXA₄ in whole blood of patients with severe asthma compared to moderate asthma was established, while the production of cysteinyl-leukotrienes and LTB₄ were increased[9]. In addition, similar findings have been reported in airway fluids for the levels of these lipid mediators; thus, an increase in LTB₄ levels was found in the supernatant of induced sputum of severe asthma patients compared to non-severe asthma. In these same samples, LXA₄ levels were highest in the mild asthma group[20,21]. Moreover, LXA₄ levels in BAL fluids from patients with severe asthma recruited in the NHLBI Severe Asthma Research Program are decreased compared to non-severe asthma patients, and BAL cells from severe asthma patients had increased 5-LO and decreased 15-LO expression [10]. These results are in line with the current observation of reduced basal and LPS-stimulated production of LXA₄ from alveolar macrophages of patients with severe asthma. In conjunction with the large number of alveolar macrophages in healthy and asthmatic lung, these observations provide support to the idea that the alveolar macrophage is a likely important source of LXA₄ in human airways.

There have been very few studies of the effect of LPS on human macrophages in terms of LT and LX generation. Brief exposure of murine macrophages to LPS can prime them to increase LT synthesis in response to an activating stimulus such as immune complexes or divalent cation ionophore A23187[22], an observation that has been subsequently shown in human AMs [23]. On the other hand, prolonged exposure to LPS impaired the capacity of rat macrophages to produce LTs in response to stimulating agents, a process that was due to the production of inhibitory substances such as nitric oxide [24,25]. LPS can induce human AM phagocytosis of apoptotic cells, but AMs from subjects with severe asthma display defective clearance mechanisms and lower levels of PGE₂ and 15-hydroxyeicosatetraenoic acid formation in response to LPS[26]. Both PGE₂ and 15-HETE can play pivotal roles in establishing LX biosynthesis [27,28].

Differences in basal LTB₄ from AMs have not been previously observed between asthma and normal atopic or non-atopic control subjects[29], or those with nocturnal...
asthma [30]. However, asthmatic subjects in these studies would not have met the NHLBI Severe Asthma Research Program's criteria for severe asthma [2]. Regarding calcium ionophore-induced LTB₄ biosynthesis by AMs, one study reported increased LTB₄ generation by cells in asthma compared to non-asthmatics [31], while another study did not report any significant differences [29]. Our study shows reduced baseline LTB₄ in non-severe asthma and no significant differences in stimulated production by LPS compared to non-asthmatics. Because LTB₄ biosynthesis by AMs in vitro can be modulated by environmental factors in vivo, such as cigarette smoking [32], smokers were excluded from the study.

Glucocorticoids have been shown to inhibit LT generation through inhibition of phospholipase A₂ activity [33,34]. Chronic oral corticosteroid therapy may lead to a suppression of eicosanoid biosynthesis and could underlie the baseline reduction in LXA₄ and LTB₄ observed in the macrophages from patients with severe asthma. Both LTB₄ and LXA₄ stimulated by calcium ionophore in the circulating neutrophil was reduced in corticosteroid-dependent asthmatics who were on oral prednisolone [35]. However, as far as the AM is concerned, there was no significant inhibition of LTB₄ from AMs of normal subjects treated with oral prednisolone despite the fact that direct incubation of these cells with dexamethasone leads to an inhibition of basal and calcium ionophore triggered formation of LTB₄ [36]. Other work also indicate that oral short-term treatment with prednisone does not inhibit the levels of the eicosanoids, PGD₂, 5-HETE and LTE₄ in BAL from asthmatic subjects at baseline or after allergen challenge [37]. However, ex-vivo treatment of BAL cells with prednisolone did cause inhibition of LTB₄ and thromboxane generation. Similarly, in the work of Wenzel et al., a single dose of oral prednisone inhibited LTB₄ release from alveolar macrophages from patients with nocturnal asthma but not from those without nocturnal asthma [30]. Only half of the patients with severe asthma in this study were on oral corticosteroid therapy and there was no significant differences in terms of LPS-induced LTB₄ or LXA₄ or of dexamethasone-induced suppression between macrophages of severe asthma patients who were on prednisolone versus those not on prednisolone. Similarly, in the non-severe asthma group, there was no difference in terms of LPS-induced LTB₄ or LXA₄ or of dexamethasone-induced suppression between macrophages of non-severe asthma patients who were on daily inhaled corticosteroids versus those not on inhaled corticosteroids. However, the influence of long-term oral or inhaled corticosteroid therapy, as contrasted to short-term, on this ex-vivo production of arachidonic acid-derived mediators cannot be entirely excluded.

We have elected to group our asthmatic patients as non-severe and severe asthma patients on the basis of the definition of severe asthma proposed by the ATS [12]. This definition of severe asthma is based on the lack of control of asthma despite taking maximal anti-inflammatory treatments with corticosteroids, while the non-severe asthma patients were those on no or only low-dose inhaled corticosteroids. We observed that there was relative CS insensitivity of LTB₄ generation but not of LXA₄ from AMs of patients with severe asthma. Previously, no differences in CS sensitivity of AMs in terms of calcium ionophore induced LTB₄ from asthmatics as compared to non-asthmatic macrophages have been reported [29]. In a previous study, we have shown that AMs from patients with severe asthma demonstrate a reduced sensitivity to dexamethasone in terms of LPS-induced release of pro-inflammatory cytokines [5].

Our data on LXA₄ is one of the first regarding its stimulated production by LPS, and its suppression by dexamethasone. Levels of anti-inflammatory LXs were low in severe asthmatics, and did not increase in response to LPS stimulation, further increasing the disparity between severe asthmatics and non-severe asthmatics in the levels of these mediators. Moreover, dexamethasone suppressed LPS-induced increases in LXA₄ in all groups. This differential response of AMs from severe asthmatics vis-a-vis LTB₄ and LXA₄ and the effect of corticosteroids (increased LTB₄ in response to LPS and impaired CS suppression of the rise in LTB₄ vs. little change in LXA₄ in response to LPS and unimpaired CS suppression of LXA₄ levels) may contribute to persistent airway neutrophilic inflammation since LXA₄ can inhibit LTB₄-induced chemotaxis, adhesion and transmigration [17]. This potential role of LXA₄ in regulating neutrophil chemotaxis is supported by the inverse relationship between baseline LXA₄ and the percentage of neutrophils in bronchoalveolar lavage fluid.

Lipoxins are a distinct class of eicosanoids with anti-inflammatory properties at subnanomolar concentrations. Thus, although the basal and stimulated levels of LXA₄ from alveolar macrophages are in low picogram amounts, these levels would be predicted to have pro-resolving actions for airway inflammation (reviewed in [17]. In support of the protective effect of LXA₄, we found a positive correlation between LPS-induced LXA₄ and lung function as represented by FEV₁. Indirectly, this protection in lung function may occur through an effect on neutrophilic inflammation, since there was an inverse correlation between BAL neutrophilia and FEV₁. LXA₄ can inhibit LTB₄-initiated chemotaxis, adhesion and transmigration. In addition, LXA₄ inhibits eosinophilic allergic inflammation [38]. Thus, a possible imbalance in
LTB₄ and LXA₄ in the airways would serve to increase airway neutrophil and eosinophil accumulation and activation. Interestingly, a similar imbalance between LT and LX generation is present in scleroderma lung disease [39] and decreased lipoxin production has also been reported in inflammatory bowel disease [40].

One of the potential limitations of our work regards the relative age of the healthy control group that were younger than the asthma groups. Generation of LXA₄ can decrease and LTB₄ increase with age [41,42], but there is no information available at present on the influence of age on the release of these eicosanoids from human alveolar macrophages. While there may be uncertainty about the effect of age, we are able to compare the non-severe with the severe group of asthmatic subjects as they were of comparable age group.

In summary, we demonstrate impaired corticosteroid modulation of the pro-inflammatory lipid mediator LTB₄ but not of the anti-inflammatory lipoxin, LXA₄, in AMs of severe asthma. Together with the augmented LPS induction of LTB₄ and decreased generation of LXA₄ in severe asthma, our observations indicate a net pro-inflammatory imbalance in severe asthma.

Abbreviations
AM: alveolar macrophage; BAL: bronchoalveolar lavage; BALF: bronchoalveolar lavage fluid; CS: corticosterone; Dex: dexamethasone; FEV₁: forced expiratory volume in one second; LT: leukotriene; LTB₄, leukotriene B₄; LPS: lipopolysaccharide; LX: lipoxin; LXA₄, lipoxin A₄; PC, PCs: provocative concentration of metacholine causing a 20% fall in FEV₁; SEM: standard error of the mean.

Competing interests
PB has no conflicts of interest to disclose. BBL is a co-inventor on patents on lipoxins that are owned by Brigham and Women’s Hospital that have been licensed for clinical development and are the subject of continuations. MH has no conflicts of interest to disclose. MP has no conflicts of interest to disclose. SK has no conflicts of interest to disclose. EI has no conflicts of interest to disclose. KFC has participated on Advisory Boards of several pharmaceutical companies to discuss treatments used for asthma and COPD. He has received unrestricted grant money from one pharmaceutical company, and other grant money to participate in clinical trials.

Authors’ contributions
KFC and BDL conceived the study, PB and MH collected the samples, MP, SK and BDL did the measurements of lipoxins, PB, BDL, EI and KFC wrote the manuscript. All the authors have read the and approved the final manuscript.

Acknowledgements
Supported by NIH-R01 grants, HL-69155, HL69349 and AI068084. Conducted in collaboration with the Severe Asthma Research Program (SARP) funded by the NHLBI and consisting of: Brigham and Women’s Hospital, Massachusetts General Hospital, the NHLBI and consisting of:

Authors' contributions
KFC and BDL conceived the study, PB and MH collected the samples, MP, SK and BDL did the measurements of lipoxins, PB, BDL, EI and KFC wrote the manuscript. All the authors have read the and approved the final manuscript.

Acknowledgements
Supported by NIH-R01 grants, HL-69155, HL69349 and AI068084. Conducted in collaboration with the Severe Asthma Research Program (SARP) funded by the NHLBI and consisting of: Brigham and Women’s Hospital—Eliot Israel, Cleveland Clinic Foundation—Seripil C. Erzurum, Emory University—W. Gerald Teague, Imperial College London—Kian Fan Chung, National Jewish Medical and Research Center—Sally E. Wenzel, University of Pittsburgh & University of Texas Medical Branch—William J. Calhoun, University of Virginia—Benjamin Gaston; University of Wisconsin—William W. Busse; Wake Forest University—Eugene R. Bleecker, Washington University in St. Louis—Mario Castro, Data Coordinating Center—James R. Murphy, NHLBI—Patricia Noel.

The authors declare that the Funding Bodies had no role in study design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Author Details
1Experimental Studies, Airways Disease Section, National Heart & Lung Institute, Imperial College London & Royal Brompton NHS Trust, London, UK and 2Pulmonary and Critical Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.

Received: 20 August 2009 Accepted: 7 June 2010

Published: 7 June 2010

References
Bhavsar et al. Respiratory Research 2010, 11:71
http://respiratory-research.com/content/11/1/71
Page 9 of 9

17. Serhan CN: Resolution Phase of Inflammation: Novel Endogenous Anti-


